Endometrioid Paraovarian Borderline Cystic Tumor in an Infant with Proteus SyndromeReport as inadecuate

Endometrioid Paraovarian Borderline Cystic Tumor in an Infant with Proteus Syndrome - Download this document for free, or read online. Document in PDF available to download.

Case Reports in Oncological Medicine - Volume 2015 2015, Article ID 392576, 6 pages -

Case Report

Department of Oncology and Radiotherapy, Rebagliati Hospital, Lima, Peru

Department of Genetics, Rebagliati Hospital, Lima, Peru

Department of Gynecology-Oncology, Rebagliati Hospital, Lima, Peru

Department of Pathology, Rebagliati Hospital, Lima, Peru

Received 21 August 2015; Revised 26 September 2015; Accepted 30 September 2015

Academic Editor: Yoshihito Yokoyama

Copyright © 2015 Liliana Vasquez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ovarian and paraovarian neoplasms are uncommon in children, mainly originating from germ cell tumors and, least frequently, epithelial tumors. There is an association between genital tract tumors and Proteus syndrome, a rare, sporadic, and progressive entity, characterized by a postnatal overgrowth in several tissues caused by a mosaic mutation in the AKT1 gene. We describe a 20-month-old asymptomatic infant with Proteus syndrome who developed an endometrioid paraovarian borderline cystic tumor. This is the youngest patient so far reported in the literature with this rare syndrome and an adnexal tumor of borderline malignancy. A total of nine patients have been described with female tract tumors and associated Proteus syndrome, which includes bilateral ovarian cystadenomas and other benign masses. A paraovarian neoplasm is extremely rare in children and could be considered a criterion for Proteus syndrome. Standardized staging and treatment of these tumors are not well established; however, most authors conclude that these neoplasms must be treated as their ovarian counterparts.

Author: Liliana Vasquez, Mariela Tello, Ivan Maza, Monica Oscanoa, Milagros Dueñas, Haydee Castro, and Alan Latorre

Source: https://www.hindawi.com/


Related documents